Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473438 | 0.83 | ELANE (0.33) | LMNAKCNN4KCNA3ELANEADRB3 | |
| SCHEMBL5322092 | 0.82 | LMNA (0.35) | LMNAKCNN4KCNA3ELANENOS1 | |
| SCHEMBL30107133 | 0.82 | KMT2A (0.36) | LMNAELANEADRB3KMT2A | |
| SCHEMBL26668633 | 0.81 | NOS1 (0.38) | KCNN4KCNA3ELANEADRB3KMT2A | |
| SCHEMBL16886284 | 0.81 | KCNN4 (0.34) | KCNN4KCNA3ELANEADRB3 | |
| SCHEMBL16422823 | 0.79 | ELANE (0.32) | KCNN4KCNA3ELANEADRB3RORC | |
| SCHEMBL26668132 | 0.79 | KCNN4 (0.34) | KCNN4ELANEADRB3PDE4B | |
| SCHEMBL18704852 | 0.79 | LMNA (0.33) | LMNAKCNN4KCNA3RORC | |
| SCHEMBL18704849 | 0.79 | LMNA (0.33) | LMNAKCNN4KCNA3 | |
| SCHEMBL30107368 | 0.78 | ADRB3 (0.37) | KCNN4KCNA3ELANEADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525875-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224894-A1 | MACROCYCLES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845540-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-07-07 | — | — | EP | disclosed |
| EP-3404032-A2 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-10081624-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-25 | — | — | US | disclosed |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-09 | — | — | US | disclosed |
| EP-3187497-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-05 | — | — | EP | disclosed |
| CN-105579457-A | Substituted N-biphenyl-3-acetylamino-benzamides and N- [3- (acetylamino) phenyl ] -biphenyl-carboxamides and their use as WNT signaling pathway inhibitors | Bayer Pharma AG | 2016-05-11 | — | — | CN | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140073-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8217070-B2 | 2-substituted-1H-benzimidazole-4-carboxamides are PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100234425-A1 | 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| US-7728026-B2 | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors | ABBOTT LABORATORIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006110683-A1 | 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229351-A1 | 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229351-A1 | 2-Substituted-1 H-benzimidazile-4-carboxamides are PARP inhibitors | PARP1, PARP2, PARP4 | LMNA 219/4885KCNN4 4379/4885KCNA3 4050/4885 |
| US-20100234425-A1 | 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS | PARP1, PARP2, PARP4 | LMNA 234/4885KCNN4 4582/4885KCNA3 4208/4885 |
| US-20180222896-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC11 | LMNA 4287/4885KCNN4 3434/4885KCNA3 2552/4885 |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | ENTPD5, NUDT1, ITPA | LMNA 4248/4885KCNN4 4236/4885KCNA3 2745/4885 |
| US-10081624-B2 | Heterocyclic compound | HDAC1, HDAC5, HDAC11 | LMNA 4287/4885KCNN4 3434/4885KCNA3 2552/4885 |
| US-20140275523-A1 | PROCESS FOR MAKING BENZOXAZEPIN COMPOUNDS | PIK3C2B, PIP4K2C, PIK3C2A | LMNA 554/4885KCNN4 408/4885KCNA3 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.